Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 75-80

  Kunos, Charles A ^a   Radivoyevitch, Tomas ^a   Waggoner, Steven ^a   Debernardo, Robert ^a   Zanotti, Kristine ^a   Resnick, Kimberly ^a   Fusco, Nancy ^a   Adams, Ramon ^a   Redline, Raymond ^a   Faulhaber, Peter ^a   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cervical cancer; Radiosensitization; Ribonucleotide reductase; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CISPLATIN; FLUORODEOXYGLUCOSE F 18; RIBONUCLEOTIDE REDUCTASE;

ABDOMINOPELVIC PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BRACHYTHERAPY; BRAIN HEMORRHAGE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DNA DAMAGE; DNA REPAIR; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ENTEROCOLITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; LIVER DYSFUNCTION; MALLORY WEISS SYNDROME; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PELVIS PAIN SYNDROME; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; UTERINE CERVIX CANCER; VAGINA CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CHEMORADIOTHERAPY; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PYRIDINES; THIOSEMICARBAZONES; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS;

EID: 84879097670     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.019     Document Type: Article

References (38)

1. P. Rose, S. Ali, E. Watkins, J. Thigpen, G. Deppe, and D. Clark-Pearson Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 2804 2810
2. F. Stehman, S. Ali, H. Keys, L. Muderspach, W. Chafe, and D. Gallup Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Am J Obstet Gynecol 197 2007 503.e1 503.e6
3. M. Candelaria, J. Chanona-Vilchis, L. Cetina, D. Flores-Estrada, C. López-Graniel, and A. González-Enciso Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma Int Semin Surg Oncol 3 2006 3 [1-8]
4. B cervical carcinoma: a Gynecologic Oncology Group Study Am J Obstet Gynecol 203 2010 351.e1 351.e8
5. 18F-fluoro-2-deoxy-d-glucose positron emission tomography standard uptake value as an indicator of cervical cancer chemoradiation therapeutic response Int J Gynecol Cancer 21 2011 1117 1123
6. R. Samant, B. Lau, E C, T. Le, and T. Tam Primary vaginal cancer treated with concurrent chemoradiation using cis-platinum Int J Radiat Oncol Biol Phys 69 2007 746 750
7. 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries J Nucl Med 50 2009 64S 73S
8. M.-L. Kuo, and T. Kinsella Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells Cancer Res 58 1998 2245 2252
9. H. Tanaka, H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, and K. Matsui A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage Nature 404 2000 42 49
10. P. Hakansson, A. Hofer, and L. Thelander Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells J Biol Chem 281 2006 7834 7841
11. J. Weidhaas, S. Li, K. Winter, J. Ryu, A. Jhingran, and B. Miller Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128 Clin Cancer Res 15 2009 4199 4206
12. C. Kunos, S. Chiu, J. Pink, and T. Kinsella Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein Radiat Res 172 2009 666 676
13. C. Kunos, T. Radivoyevitch, J. Pink, S. Chiu, T. Stefan, and J. Jaccobberger Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers Radiat Res 174 2010 574 581
14. C. Kunos, V. Colussi, J. Pink, T. Radivoyevitch, and N. Oleinick Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low dose rates Int J Radiat Oncol Biol Phys 80 2011 1198 1204
15. C. Kunos, G. Ferris, N. Pyatka, J. Pink, and T. Radivoyevitch Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers Radiat Res 176 2011 425 433
16. M.M. Hreshchyshyn, B.S. Aron, R.C. Boronow, E.W. Franklin III, H.M. Shingleton, and J.A. Blessing Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis Int J Radiat Oncol Biol Phys 5 1979 317 322
17. P.J. Eifel, K. Winter, M. Morris, C. Levenback, P.W. Grigsby, and J. Cooper Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01 J Clin Oncol 22 2004 872 880
18. C.W. Whitney, W. Sause, B.N. Bundy, J.H. Malfetano, E.V. Hannigan, and W.C. Fowler Jr. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study J Clin Oncol 17 1999 1339 1348
19. A. Duenas-Gonzalez, J. Zarba, F. Patel, J. Alcedo, F. Beslija, and L. Casanova A phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix J Clin Oncol 29 2011 1678 1685
20. C. Kunos, S. Waggoner, V. Von Gruenigen, E. Eldermire, J. Pink, and A. Dowlati Phase I trial of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with pelvic radiation therapy and weekly cisplatin chemotherapy for locally advanced cervical cancer Clin Cancer Res 16 2010 1298 1306
21. C. Kunos, T. Radivoyevitch, S. Ingalls, and C. Hoppel Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone induced methemoglobinemia Future Oncol 8 2012 145 150
22. C. Kunos Therapeutic mechanisms of treatment in cervical and vaginal cancer Oncol Hematol Rev 8 2012 55 60
23. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 2006 1059 1066
24. 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations Eur J Cancer 35 1999 1771 1782
25. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
26. R. Simon, B. Freidlin, L. Rubinstein, S. Arbuck, J. Collins, and M. Christian Accelerated titration designs for phase 1 clinical trials in oncology J Natl Cancer Inst 89 1997 1138 1147
27. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
28. R. Newcombe Two-sided confidence intervals for the single proportion: comparison of seven methods Stat Med 17 1998 857 872
29. P.G. Rose, B.N. Bundy, E.B. Watkins, J.T. Thigpen, G. Deppe, and M.A. Maiman Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153
30. C. Kunos, T. Radivoyevitch, J. Pink, S. Chiu, T. Stefan, and J. Jacobberger Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers Radiat Res 174 2010 574 581
31. P. Olive, and J. Banath Kinetics of H2AX phosphorylation after exposure to cisplatin Cytometry Part B 76B 2009 79 90
32. C. Kunos, T. Radivoyevitch, F. Abdul-Karim, J. Fanning, O. Abulafia, and A. Bonebrake Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group study J Transl Med 10 2012 79 [1-10]
33. R. Pötter, P. Georg, J. Dimopoulos, M. Grimm, D. Berger, and N. Nesvacil Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer Radiother Oncol 100 2011 116 123
34. J. Dimopoulos, M. Schmid, E. Fidarova, D. Berger, C. Kirisits, and R. Pötter Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results Int J Radiat Oncol Biol Phys 82 2012 1880 1888
35. C. Kunos, G. Ferris, and S. Waggoner Implementing chemoradiation treatment for patients with cervical cancer in a comprehensive cancer center community oncology practice Commun Oncol 7 2010 446 450
36. C. Kunos, H. Gibbons, F. Simpkins, and S. Waggoner Chemotherapy administration during pelvic radiation for cervical cancer patients aged ≥ 55 years in the SEER-Medicare population J Oncol 2008 2008 1 7
37. C. Kunos, C. Tian, S. Waggoner, P. Rose, and R. Lanciano Retrospective analysis of concomitant cisplatin during radiation in patients aged ≥ 55 years for treatment of advanced cervical cancer: a Gynecologic Oncology Group Study Int J Gynecol Cancer 19 2009 1258 1263
38. J. Chao, T. Synold, R. Morgan Jr., C. Kunos, J. Longmate, and H.-J. Lenz A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced stage solid cancers-a California Cancer Consortium Study Cancer Chemother Pharmacol 69 2012 835 843